Danaher Corporation

Danaher Corporation

DHR
Danaher CorporationUS flagNew York Stock Exchange
176.11
USD
-3.76
- -
124.65BMarket Cap
Danaher Corporation
DHR
(New York Stock Exchange)

Recent

price

178.08

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
19.21
23.8
26.33
26.27
18.32
20.68
24.42
22.3
24.33
25.05
31.55
34.71
36.74
32.44
32.66
34.47
34.87
Revenue per Share
2.74
3.21
3.45
3.87
3.7
4.81
3.69
3.58
3.78
4.11
4.97
8.77
9.8
6.44
5.33
5.07
5.19
Basic EPS, GAAP
2.9
3.39
4.26
4.38
4.69
4.71
4.24
4.18
4.91
4.64
7.67
9.96
10.21
7.85
7.24
7.38
7.45
Free Cash Flow per Basic Share
0.08
0.09
0.12
0.07
0.32
0.51
1.28
0.54
0.62
1.05
0.87
1.04
1.13
1.69
1.05
1.23
1.28
Dividend per Share
16.77
19.32
22.19
25.88
28.95
30.11
29.96
32.79
35.93
33.81
38.47
45.95
54.08
55.78
60.46
65.81
67.05
Book Value per Share
-0.47
-4.94
-3.93
0.24
1.02
-11.17
-18.18
-15
-6.62
-5.29
-28.59
-30.95
-11.96
-12.04
-13.02
-11.82
-9.81
Tangible Book Value per Share
653
676
693
696
702
698
691
696
701
715
706
715
725
736
731
713
711
Basic Weighted Avg Shares
12,550
16,090
18,260
18,283
12,867
14,434
16,882
15,519
17,049
17,911
22,284
24,802
26,643
23,890
23,875
24,568
24,778
Sales/Revenue/Turnover
16.15
15.85
16.95
17.07
15.89
14.98
16.2
16.58
17.92
18.25
18.99
25.75
28.29
21.77
20.37
19.09
19.21
Operating Margin (%)
388
635
840
851
718
881
1,128
1,117
1,178
1,189
1,775
2,062
2,132
2,166
2,352
2,447
2,483
Depreciation Expense
1,793
2,172
2,392
2,695
2,598
3,357
2,554
2,492
2,651
3,008
3,646
6,433
7,209
4,764
3,899
3,614
3,689
Net Income, GAAP
22.94
20.94
23.63
24.17
21.45
14.35
17.54
14.59
18.77
26.41
18.89
16.34
11.45
16.32
16.08
14.95
15.3
Effective Tax Rate (%)
14.29
13.5
13.1
14.74
20.19
23.26
15.13
16.06
15.55
16.79
16.36
25.94
27.06
19.94
16.33
14.71
14.89
Profit Margin (%)
2,425
2,100
3,382
4,586
4,035
1,666
-209
2,058
2,252
20,664
6,400
3,508
7,494
5,663
2,699
5,949
6,475
Working Capital
2,784
5,207
5,288
3,437
3,402
12,025
9,674
10,327
9,688
22,156
21,978
23,057
19,858
17,661
16,468
19,495
17,561
LT Debt
13,773
16,972
19,084
22,451
23,450
23,764
23,077
26,368
28,227
30,282
39,777
45,177
50,090
53,490
49,550
52,541
52,957
Total Equity
10.02
10.34
10.08
9.36
6.01
5.76
6.23
6.04
6.59
5.27
5.95
8.13
9.52
6.02
5.8
5.71
5.82
Return on Invested Capital (%)
14.5
14.15
12.81
13.22
11.76
12.02
8.07
7.87
8.09
7.42
7.67
11.83
12.23
8.19
6.78
6
6.12
Return on Capital (%)
17.79
18.09
16.82
16.14
13.55
16.24
12.24
11.45
11.05
11.92
13.67
20.9
19.72
11.81
9.14
7.93
7.97
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
23
201
923
LT Borrowings
16,833
18,416
17,561
LT Finance Leases
- -
1,079
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
706
707
708
Market Capitalization
142,063
163,151
134,730

Working Capital

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
9,606
12,756
13,935
Cash, Cash Equivalents & STI
1,528
4,615
5,701
Accounts Receivable, Net
3,755
3,913
3,819
Inventories
2,674
2,489
2,608
Total Current Liabilities
6,324
6,807
7,460
Payables & Accruals
6,301
2,451
6,537
ST Debt
23
201
923
Deferred Revenue
- -
1,353
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.7%
5.98%
6.04%
Free Cash Flow
7.08%
0.88%
-0.68%
Net Income, GAAP
4.38%
5.82%
-7.31%
Sales/Revenue/Turnover
5.95%
2.25%
2.9%
Total Cash Common Dividend
22.81%
18.62%
14.32%

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5,796
5,743
5,798
6,538
23,875
2025
5,741
5,936
6,053
6,838
24,568
2026
5,951
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.47
1.23
1.13
1.5
5.33
2025
1.33
0.77
1.28
1.69
5.07
2026
1.45
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.24
0.27
0.27
0.27
1.05
2025
0.27
0.32
0.32
0.32
1.23
2026
0.32
- -
- -
- -
- -
Business
Danaher Corporation (NYSE: DHR), founded in 1984 and headquartered in Washington, D.C., operates as a leading global science and technology innovator focused on life sciences and diagnostics. The company conducts business through three primary segments: biotechnology, which develops products and services for therapeutic development including bioprocessing solutions, plasmid DNA, mRNA, proteins, and genomic medicines via brands such as Cytiva, Aldevron, and Abcam; life sciences, offering instruments like mass spectrometers, flow cytometry systems, microscopes, genomics consumables, lab automation, centrifugation, particle characterization, and gene and cell therapy tools; and diagnostics, providing clinical instruments, reagents, consumables, software, and services for disease diagnosis in hospitals, physicians' offices, reference laboratories, and critical care settings through subsidiaries including Cepheid and Beckman Coulter. Danaher serves customers worldwide across biopharmaceutical, research, healthcare, and precision medicine markets, employing approximately 63,000 associates in over 125 countries. Recent developments include the 2023 acquisition of Abcam for proteomic research consumables to accelerate drug discovery; a January 2025 investment partnership with Innovaccer Inc. through Danaher Diagnostics LLC and Danaher Ventures LLC to advance AI-enabled diagnostics and precision medicine; and a May 2025 diagnostic development and commercialization alliance with AstraZeneca to scale next-generation AI-powered diagnostics solutions.

Company News

APIChat
  • Here Are Tuesday’s Top Wall Street Analyst Research Calls: CoreWeave, Danaher, Hewlett Packard Enterprise, Intuit, Knight-Swift, Meta Platforms, Starwood Property Trust, Tripadvisor, and More

  • SCIEX Advances the ZenoTOF Line With Platform-Wide Expansions in Software, Integrations, and Key Collaborations

  • SCIEX Launches the novus V55 System With SCIEX OS 5.0 Software and AI Enablement Tools

  • A Look at Danaher Corp (DHR) After 4.3% Gain -- GF Value $236.05 vs Price $180.63

  • 11 'Safer' Dividend Dogs Lead 20 May Barron's 2026 Oil And Blue Chips

  • Why Is Danaher (DHR) Down 7% Since Last Earnings Report?

  • Strength in Danaher's Biotechnology Unit Seems Firm: More Upside Ahead?

  • Here Are Friday’s Top Wall Street Analyst Research Calls: Arista Networks, BWX Technologies, Cisco Systems, Danaher, Doximity, Estee Lauder, Illumina, Texas Roadhouse, Workday, and More

  • Danaher Corporation (DHR) Presents at Bank of America Global Healthcare Conference 2026 Transcript

  • Danaher to Present at Bank of America Securities Healthcare Conference

  • Danaher Announces Quarterly Dividend

  • Masimo Shareholders Approve Acquisition by Danaher

  • Xylem Q1 Earnings Beat Estimates, Revenues Increase Y/Y

  • Danaher Corporation $DHR Shares Purchased by AEGON ASSET MANAGEMENT UK Plc

  • Calamos Advisors LLC Has $55.79 Million Stock Position in Danaher Corporation $DHR

  • This Stock Is Up Over 52,700% Since Founding. Should Investors Buy After Its 36% Decline?

  • Arizona State Retirement System Sells 6,790 Shares of Danaher Corporation $DHR

  • Danaher reaches $172.5 million settlement with shareholders over post-pandemic outlook

  • Danaher Announces Pricing of Euro-Denominated Senior Notes Offering

  • Danaher Q1 2026 Earnings Update